Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which ablation method best tames persistent AF? a Head-to-Head trial aims to find out

NCT ID NCT07726901

Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This trial compares two catheter ablation strategies for people with persistent atrial fibrillation (AF). One group receives standard pulmonary vein isolation using pulsed-field ablation; the other receives radiofrequency ablation followed by additional map-guided targeting of abnormal heart tissue. Researchers will track which approach better prevents atrial arrhythmias over one year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
catheter ablation (pulsed-field ablation or radiofrequency ablation with map-guided substrate modification)
What this could lead to
If one strategy proves superior, it could establish a more effective standard approach for treating persistent atrial fibrillation, potentially reducing recurrence and the need for repeat procedures.
What could go wrong
This is a single-center trial, and results may not apply to all patients. Both procedures carry risks such as bleeding, heart damage, or arrhythmia recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 360 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 19 years or older who have voluntarily provided written informed consent to participate in the study * Patients diagnosed with persistent atrial fibrillation (AF) who are scheduled to undergo catheter ablation for AF. Exclusion Criteria: * History of prior catheter ablation or MAZE surgery for atrial fibrillation. * Left atrial (LA) diameter exceeding 60 mm. * Patients with end-stage renal disease (ESRD). * History of prior open-heart surgery. * Women who are pregnant, lactating, or of childbearing potential. * Heart failure corresponding to New York Heart Association (NYHA) functional class IV. * Acute coronary syndrome (ACS) experienced within the past 3 months. * Patients with terminal illness and a life expectancy of less than one year. * Any other condition that the investigator deems inappropriate for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Samsung Medical Center

    NOT_YET_RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Samsung Medical Center

    RECRUITING

    Seoul, Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.